Table 1.
Clinical response definitions.
Fig 1.
Pafuramidine (DB289) Phase 3 study CONSORT flowchart.
Table 2.
Baseline demographics.
Table 3.
Combined rate of cure and probable cure at 12 months.
Table 4.
Combined rate of cure and probable cure at 24 months.
Table 5.
Secondary efficacy variables at months 3, 6, 12, 18, and 24 (per-protocol dataset).
Table 6.
Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treatment period).